AU2018379996A1 - Methods and compositions to prevent microbial infection - Google Patents

Methods and compositions to prevent microbial infection Download PDF

Info

Publication number
AU2018379996A1
AU2018379996A1 AU2018379996A AU2018379996A AU2018379996A1 AU 2018379996 A1 AU2018379996 A1 AU 2018379996A1 AU 2018379996 A AU2018379996 A AU 2018379996A AU 2018379996 A AU2018379996 A AU 2018379996A AU 2018379996 A1 AU2018379996 A1 AU 2018379996A1
Authority
AU
Australia
Prior art keywords
gene
microorganism
weeks
synthetic
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018379996A
Other languages
English (en)
Inventor
Ravi S. V. Starzl
Timothy W. Starzl
Todd D. Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioplx Inc
Original Assignee
Bioplx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioplx Inc filed Critical Bioplx Inc
Publication of AU2018379996A1 publication Critical patent/AU2018379996A1/en
Priority to AU2025234199A priority Critical patent/AU2025234199A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/002—Vectors comprising a special origin of replication system inducible or controllable
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/55—Vectors comprising a special origin of replication system from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/55—Vectors comprising a special translation-regulating system from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/44—Staphylococcus
    • C12R2001/445—Staphylococcus aureus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018379996A 2017-12-05 2018-12-04 Methods and compositions to prevent microbial infection Abandoned AU2018379996A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025234199A AU2025234199A1 (en) 2017-12-05 2025-09-18 Methods and compositions to prevent microbial infection

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762594943P 2017-12-05 2017-12-05
US62/594,943 2017-12-05
PCT/US2018/063880 WO2019113096A1 (en) 2017-12-05 2018-12-04 Methods and compositions to prevent microbial infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025234199A Division AU2025234199A1 (en) 2017-12-05 2025-09-18 Methods and compositions to prevent microbial infection

Publications (1)

Publication Number Publication Date
AU2018379996A1 true AU2018379996A1 (en) 2020-06-25

Family

ID=66658442

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018379996A Abandoned AU2018379996A1 (en) 2017-12-05 2018-12-04 Methods and compositions to prevent microbial infection
AU2025234199A Pending AU2025234199A1 (en) 2017-12-05 2025-09-18 Methods and compositions to prevent microbial infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025234199A Pending AU2025234199A1 (en) 2017-12-05 2025-09-18 Methods and compositions to prevent microbial infection

Country Status (9)

Country Link
US (2) US12163135B2 (enExample)
EP (1) EP3720458B1 (enExample)
JP (2) JP7460531B2 (enExample)
CN (2) CN111918960B (enExample)
AU (2) AU2018379996A1 (enExample)
CA (1) CA3084954A1 (enExample)
MX (1) MX2020005875A (enExample)
PH (1) PH12020550941A1 (enExample)
WO (1) WO2019113096A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104805066B (zh) * 2015-05-18 2018-04-24 武汉菲吉乐科生物科技有限公司 一种葡萄球菌裂解酶及其应用
TWI718402B (zh) * 2018-08-16 2021-02-11 葡萄王生技股份有限公司 副乾酪乳酸桿菌gks6之活性物質、含其之組合物及其促進長壽之用途
EP3984546A4 (en) * 2019-05-15 2023-09-27 Universidad de Granada Gene therapy with the genes hokd and ldrb for cancer treatments
EP3996510A4 (en) * 2019-07-08 2023-08-09 BioPlx, Inc. LIVING BIOTHERAPEUTIC COMPOSITIONS AND PROCESSES
WO2021163223A1 (en) * 2020-02-10 2021-08-19 The Research Foundation For The State University Of New York Using resilient systems inference for estimating hospital acquired infection prevention infrastructure performance
EP4110269A4 (en) 2020-02-28 2024-01-17 Emory University PENTAGALLOYL GLUCOSE FROM SCHINUS PLANTS AND METHOD OF USE
JP2023528476A (ja) * 2020-06-02 2023-07-04 バイオピーエルエックス，インコーポレイティド 組み換え微生物においてゲノムに安定に組み込むための方法
CN111926048B (zh) * 2020-07-20 2023-09-26 广东省微生物研究所（广东省微生物分析检测中心） 烯丙基硫醚在制备促进铜绿假单胞菌叶酸生物合成制剂中的应用
WO2023023560A1 (en) * 2021-08-17 2023-02-23 Contrafect Corporation New uses
US12535933B2 (en) 2021-11-16 2026-01-27 Benuka Health, Llc Systems, methods and devices for aiding in the decolonization of bacteria
CN114015622A (zh) * 2021-12-14 2022-02-08 塔里木大学 无乳链球菌培养基及其制备方法
CN114214354A (zh) * 2021-12-31 2022-03-22 天津科技大学 一种双载体表达体系及其构建方法与应用
CN116617373A (zh) * 2022-02-14 2023-08-22 菲吉乐科(南京)生物科技有限公司 一种高效葡萄球菌噬菌体粉剂及其制备方法
CN116179654B (zh) * 2022-12-30 2023-09-15 军事科学院军事医学研究院环境医学与作业医学研究所 一种检测水中镉离子的滚环扩增检测体系及其应用
CN117106674B (zh) * 2023-10-23 2024-03-08 新益(天津)生物科技有限责任公司 一株能够降低尿酸、修复女性私处微生态平衡的植物乳杆菌opb15和应用
CN119055779B (zh) * 2024-07-31 2025-11-21 中国科学技术大学 金黄色葡萄球菌毒素蛋白相关基因sa1833/sa1832在治疗金黄色葡萄球菌感染中的应用

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133875A (en) 1978-02-23 1979-01-09 Forsyth Dental Infirmary For Children Method of controlling dental caries with streptococcus mutans mutant strains
US4548807A (en) 1983-08-03 1985-10-22 Geoffrey J. Westfall Mastitis prevention
US4716032A (en) 1983-08-03 1987-12-29 Geoffrey J. Westfall Aerosol spray composition for mastitis prevention
AU7232087A (en) 1986-03-26 1987-10-20 Genexpress Aps Biological containment
DE69310339T2 (de) 1993-02-19 1997-08-21 Philippe Djian Präparate, die Corneozyt Proteine enthalten
US5733540A (en) 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
US5607672A (en) 1995-06-07 1997-03-04 University Of Florida Research Foundation, Inc. Replacement therapy for dental caries
ATE312934T1 (de) 1995-06-07 2005-12-15 Univ Washington Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit
US6593114B1 (en) * 1996-01-05 2003-07-15 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US6737248B2 (en) 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
GB9604045D0 (en) 1996-02-26 1996-04-24 Smithkline Beecham Plc Novel compounds
AUPN880996A0 (en) 1996-03-20 1996-04-18 Arnott's Biscuits Limited Selection and/or enhancement of resident microorganisms in the gastrointestinal tract
US6645506B1 (en) 1997-04-18 2003-11-11 Ganeden Biotech, Inc. Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil
DE69942249D1 (de) 1998-05-07 2010-05-27 Univ Bruxelles Auf cytotoxinen basierendes biologisches einschlusssystem
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CN1670217A (zh) 1999-02-03 2005-09-21 特瓦药厂有限公司 经微生物学方法制备假单胞菌酸a抗生素的方法
US6417002B1 (en) * 1999-02-11 2002-07-09 Pharmacopeia, Inc. Method for maintenance and selection of episomes
CN1230206C (zh) 2000-01-11 2005-12-07 内立蒂克斯股份有限公司 作为生产生物复合材料的生物可降解基质的聚合物混合物
WO2001095876A1 (en) 2000-06-09 2001-12-20 Baylor College Of Medicine The combination of antimicrobial agents and bacterial interference to coat medical devices
US6551828B1 (en) * 2000-06-28 2003-04-22 Protemation, Inc. Compositions and methods for generating expression vectors through site-specific recombination
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AU2001286741A1 (en) 2000-08-25 2002-03-04 Trustees Of Tufts College Methods and compositions for potentiating antibiotic action against persistent/tolerant pathogenic microorganisms
US7623971B2 (en) 2000-09-25 2009-11-24 Acuabiotec Llc Method, system and computer program product for technical management and biocontrol of disease in animal production systems
US20020192741A1 (en) 2000-09-28 2002-12-19 Mckillip John L. Selective medium for gram-positive bacteria
US6660262B2 (en) 2001-09-28 2003-12-09 Bovine Health Products, Inc. Broad spectrum antimicrobial compound and treatment
ATE516356T1 (de) * 2001-12-21 2011-07-15 Biosynexus Inc Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung
US20040241150A1 (en) 2002-12-19 2004-12-02 Hargis Billy M. Defined competitive exclusion cultures for food borne pathogens
US7482023B2 (en) 2003-01-03 2009-01-27 Sca Hygiene Products Ab Hygiene tissue with lactic acid producing bacterial strains
ES2395404T3 (es) 2004-05-14 2013-02-12 Optimer Pharmaceuticals, Inc. Tratamiento de las enfermedades asociadas al uso de antibióticos
US8729013B2 (en) 2004-08-26 2014-05-20 The University Of Western Ontario Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
US7627437B2 (en) 2005-01-14 2009-12-01 Idaho Research Foundation Categorization of microbial communities
US20060257373A1 (en) 2005-05-10 2006-11-16 National Chung Hsing University Antifungal formulation containing Streptomyces s.p.p., method for preparing the composition and relevant use
KR100844581B1 (ko) * 2005-05-17 2008-07-09 주식회사 뉴젝스 혈청반응성 프로모터를 가진 리포터 아데노바이러스를 이용한 고속생리활성 물질의 검색 방법
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8852916B2 (en) 2010-01-22 2014-10-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with microorganisms
US20100260794A1 (en) 2006-03-20 2010-10-14 Vrije Universiteit Brussel Live attenuated salmonella vaccine
US20080107699A1 (en) 2006-10-25 2008-05-08 Mark Spigelman Method of using topical probiotics for the inhibition of surface contamination by a pathogenic microorganism and composition therefor
GB0624340D0 (en) 2006-12-06 2007-01-17 Nature Therapeutics Ltd Antimicrobial composition
WO2008077229A1 (en) 2006-12-22 2008-07-03 Luquet Francois-Marie Growth inhibition of microorganisms by lactic acid bacteria
EP2124976B1 (en) 2006-12-22 2011-09-28 Bio-K Plus International Inc. Growth inhibition and elimination of methicillin-resistant staphylococcus aureus by lactic acid bacteria
EP2229432A4 (en) 2007-09-05 2011-05-11 Inst Nat Rech Scient ANTIMICROBIAL ACTIVITY OF BACTERIOCIN-PRODUCING MILKY ACID BACTERIA
US20110008303A1 (en) 2008-03-17 2011-01-13 Cedars-Sinai Medical Center Methods for treatment and prevention of mrsa/mssa
US9636196B2 (en) 2008-06-13 2017-05-02 ProBiora Health, LLC Use of hydrogen peroxide-producing bacteria for tooth whitening
WO2009152298A1 (en) 2008-06-13 2009-12-17 Zeus Scientific, Inc. Methods, compositions and and diagnostic kits for the detection and treatment for staphylococcal nasal decolonization using achromopeptidase
US9700611B2 (en) 2008-06-23 2017-07-11 Mississippi State University Live attenuated catfish vaccine and method of making
GB2475005A (en) 2008-08-01 2011-05-04 Ondine Int Ltd Composition and method for treatment of mrsa
WO2010036876A2 (en) 2008-09-25 2010-04-01 New York University Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
WO2010123599A2 (en) 2009-01-23 2010-10-28 The Board Of Trustees Of The University Of Illinois Anti-bacterial compositions and methods including targeting virulence factors of staphylococcus aureus
MX355507B (es) 2009-03-09 2018-04-19 Bioatla Llc Proteinas mirac.
GB0909909D0 (en) 2009-06-09 2009-07-22 Chrisal Nv Microcapsules containing microrgnisms
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
MX348611B (es) 2009-12-31 2017-06-21 Milton Trachtman Ira Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.
WO2011085367A2 (en) 2010-01-11 2011-07-14 Oragenics, Inc. Non-replicating microorganisms as post-biotics
WO2013052174A2 (en) 2011-06-06 2013-04-11 The Trustees Of The University Of Pennsylvania Methods for preventing and treating staphylococcus aureus colonization, infection, and disease
US9107938B2 (en) 2010-09-30 2015-08-18 The Board Of Trustees Of The University Of Arkansas Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads
CA2818827C (en) 2010-11-23 2024-02-13 Pantheryx, Inc. Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
EP2693887B1 (en) 2011-04-06 2020-10-28 The Board of Regents of the University of Texas System Modulating bacterial mam polypeptides in pathogenic disease
WO2012150269A1 (en) 2011-05-03 2012-11-08 Dupont Nutrition Biosciences Aps Probiotic bacteria for the topical treatment of skin disorders
EP3777885A1 (en) 2011-06-19 2021-02-17 New York University Methods of treating and preventing staphylococcus aureus infections and associated conditions
ES2674583T3 (es) 2011-06-30 2018-07-02 Exxonmobil Research And Engineering Company Regulación de genes de toxina y antitoxina para el confinamiento biológico
EP2731600A4 (en) 2011-07-13 2015-08-26 Microbiotix Inc INHIBITORS OF THE TYPE III BACTERIAL SECRETION SYSTEM
CN102887952A (zh) 2011-07-21 2013-01-23 广州瑞博奥生物科技有限公司 具有双重结合活性的抗MRSA-PBP 2a的单克隆抗体
EP2734229B1 (en) 2011-07-22 2019-01-02 Novadigm Therapeutics, Inc. Methods and copositions for vaccinating against staphylococcus aureus
WO2013050590A1 (en) * 2011-10-07 2013-04-11 Universite De Rennes 1 Spra1 antimicrobial peptides and uses thereof
CN104105471B (zh) 2012-02-14 2018-03-13 宝洁公司 皮肤共生益生元剂和包含其的组合物的局部使用
CA2865620A1 (en) 2012-03-05 2013-09-12 University Of Maryland, Baltimore Multivalent vaccine protection from staphylococcus aureus infection
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
AU2013252888B2 (en) 2012-04-26 2018-06-14 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during Staphylococcus aureus disease
ES2728782T3 (es) * 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
MX2015006491A (es) 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
EP2941259A4 (en) 2013-01-04 2016-07-27 Second Genome Inc MIKROBIOMMODULATIONSINDEX
MX369877B (es) 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
WO2014124226A1 (en) 2013-02-07 2014-08-14 The Rockefeller University Sequence specific antimicrobials
US10413577B2 (en) 2013-02-22 2019-09-17 The Regents Of The University Of California Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life
WO2014137906A1 (en) 2013-03-05 2014-09-12 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the detection, screening, isolation and sequencing of mrsa, mssa, staphylococcus markers, and the antibiotic resistance gene mec a
US9101597B2 (en) 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
US10150982B2 (en) 2013-03-14 2018-12-11 Second Genome, Inc. Microbial ecology shift assay
JP2016519664A (ja) 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド ネットワークを基にした微生物組成物及び方法
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
CN110420316A (zh) 2013-06-18 2019-11-08 纽约大学 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素：新型治疗靶点
CN110564663B (zh) 2013-08-19 2023-03-10 辛格隆股份公司 微生物的受控生长
WO2015048364A1 (en) 2013-09-27 2015-04-02 President And Fellows Of Harvard College Recombinant cells and organisms having persistent nonstandard amino acid dependence and methods of making them
US10058576B2 (en) * 2013-10-03 2018-08-28 The Trustees Of The University Of Pennsylvania Compositions and methods comprising a defined microbiome and methods of use thereof
WO2015069682A2 (en) 2013-11-05 2015-05-14 President And Fellows Of Harvard College Precise microbiota engineering at the cellular level
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
AU2014363987A1 (en) 2013-12-09 2016-06-30 Janssen Biotech, Inc. Compositions and methods for phagocyte delivery of anti-staphylococcal agents
EP3903824A1 (en) 2014-01-10 2021-11-03 The Regents of The University of California Skin probiotic
CN106456678A (zh) 2014-04-15 2017-02-22 Ao生物医学有限责任公司 氨氧化型亚硝化单胞菌菌株d23
US20170081707A1 (en) 2014-05-06 2017-03-23 Phylagen, Inc. Monitoring and managing a facility microbiome
EP4299122A3 (en) 2014-05-07 2024-03-27 The Regents of The University of California Compositions and methods for treating skin and mucous membrane diseases
ES2929579T3 (es) 2014-05-30 2022-11-30 Azitra Inc Tratamiento terapéutico de enfermedades cutáneas con microorganismos cutáneos comensales recombinantes
CN106572662A (zh) 2014-06-27 2017-04-19 凯恩生物科技有限公司 抗微生物‑抗生物膜组合物及其作为个人护理产品的使用方法
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
WO2016066784A1 (en) * 2014-10-31 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Cyclic antimicrobial pseudopeptides and uses thereof
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
MX383245B (es) * 2014-12-05 2025-03-13 Synlogic Operating Co Inc Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
EP3064072A1 (en) 2015-02-11 2016-09-07 AB-Biotics S.A. Probiotic lactobacillus strains for use in treating urinary tract infections
KR20170121291A (ko) 2015-03-02 2017-11-01 신로직 인코포레이티드 감소된 창자 염증 및/또는 강화된 창자 점막 장벽으로부터 이익을 얻는 질병을 치료하기 위해 공학처리된 박테리아
WO2016172196A1 (en) 2015-04-20 2016-10-27 Pätzold Bernhard Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains
WO2016172686A1 (en) 2015-04-24 2016-10-27 The Translational Genomics Research Institute Compositions and methods for augmenting the nasal microbiome
WO2016177682A1 (en) 2015-05-06 2016-11-10 Snipr Technologies Limited Altering microbial populations & modifying microbiota
EP3882259B1 (en) 2015-05-13 2026-01-28 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
EP3294757B1 (en) 2015-05-13 2023-12-27 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
AU2016274311A1 (en) 2015-06-10 2018-01-18 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
AU2016279062A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
WO2016210373A2 (en) * 2015-06-24 2016-12-29 Synlogic, Inc. Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
WO2016210384A2 (en) 2015-06-25 2016-12-29 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
WO2017008018A1 (en) 2015-07-09 2017-01-12 Massachusetts Institute Of Technology Genetically engineered sensors for in vivo detection of bleeding
EP3328988A1 (en) 2015-07-31 2018-06-06 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
WO2017059245A2 (en) 2015-09-30 2017-04-06 Trustees Of Boston University Deadman and passcode microbial kill switches
EP3368050A1 (en) 2015-10-26 2018-09-05 Crestovo Holdings LLC Compositions and methods for fecal microbiota-related therapy
EP3379935A4 (en) 2015-11-25 2019-08-28 Memorial Sloan-Kettering Cancer Center METHOD AND COMPOSITIONS FOR REDUCING VANCOMYCIN RESISTANT ENTEROKOKKEN
RU2662310C9 (ru) 2015-12-04 2018-09-21 Виктор Вениаминович Тец Средство (варианты) и способы восстановления микрофлоры
LT6463B (lt) 2015-12-10 2017-10-10 Uab "Probiosanus" Probiotinių bakterijų (pb) gyvybingumo ir stabilumo padidinimas detergentų turinčiuose asmens higienos ir buities priežiūros produktuose
GB201522153D0 (en) * 2015-12-15 2016-01-27 Univ Southampton Meningococcal infection and modified neisseria lactamica
WO2017112620A1 (en) 2015-12-22 2017-06-29 North Carolina State University Methods and compositions for delivery of crispr based antimicrobials
WO2017123676A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof
US10689644B2 (en) 2016-03-17 2020-06-23 Duke University Systems and methods for genetic analysis of intractable microbes
EP3445330B1 (en) 2016-04-19 2022-07-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of gram negative species to treat atopic dermatitis
WO2017182796A1 (en) 2016-04-19 2017-10-26 Genome Research Limited Bacteriotherapy
EP3448398A4 (en) 2016-04-21 2019-12-18 Naked Biome, Inc. COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES
WO2017210428A1 (en) 2016-06-01 2017-12-07 Crestovo Llc Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders
CA3028031C (en) 2016-06-22 2023-02-28 Prodigest Bvba Microbial carotenoids affecting gut microbial composition
WO2018049556A1 (en) 2016-09-13 2018-03-22 The Procter & Gamble Company Methods of increasing microbial diversity of a skin microbiota
BR112019005810A2 (pt) 2016-09-27 2019-06-25 uBiome, Inc. método para sequenciamento de microbioma melhorado para caracterizar uma afecção relacionada a micro-organismo para um usuário associado a uma amostra biológica, e método para sequenciamento de microbioma melhorado
WO2018094190A2 (en) 2016-11-18 2018-05-24 Sanford Burnham Prebys Medical Discovery Institute Gut microbiota and treatment of cancer
US11674128B2 (en) 2016-12-12 2023-06-13 Tsinghua University Engineering of a minimal SaCas9 CRISPR/Cas system for gene editing and transcriptional regulation optimized by enhanced guide RNA
US11566238B2 (en) 2016-12-15 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
FR3060393A1 (fr) 2016-12-16 2018-06-22 Nestle Skin Health Sa Capsule comprenant un microorganisme probiotique pour utilisation dans un dispositif de production et de distribution de compositions
EP3358015A1 (en) 2017-02-03 2018-08-08 Eligo Bioscience Optimized vector for delivery in microbial populations
WO2018152306A1 (en) 2017-02-15 2018-08-23 President And Fellows Of Harvard College Modulation of host immune cell populations using gut microbiota
JP2020508357A (ja) 2017-02-27 2020-03-19 コンティニュアム グループ エルエルシー 日焼け止め剤
WO2018182515A1 (en) 2017-03-27 2018-10-04 Agency For Science, Technology And Research Methods of modifying fungi and uses thereof
US20200056145A1 (en) 2017-04-17 2020-02-20 The Regents Of The University Of California Engineered commensal bacteria and methods of use

Also Published As

Publication number Publication date
EP3720458A1 (en) 2020-10-14
WO2019113096A1 (en) 2019-06-13
US20190169623A1 (en) 2019-06-06
CN111918960B (zh) 2025-01-28
JP2021505197A (ja) 2021-02-18
CN111918960A (zh) 2020-11-10
AU2025234199A1 (en) 2026-01-22
JP2024075688A (ja) 2024-06-04
CA3084954A1 (en) 2019-06-13
US20250346910A1 (en) 2025-11-13
JP7460531B2 (ja) 2024-04-02
MX2020005875A (es) 2020-10-08
EP3720458B1 (en) 2026-07-15
CN119875972A (zh) 2025-04-25
EP3720458A4 (en) 2021-12-08
US12163135B2 (en) 2024-12-10
PH12020550941A1 (en) 2021-05-17

Similar Documents

Publication Publication Date Title
US20250346910A1 (en) Methods and compositions to prevent microbial infection
US20220288135A1 (en) Live biotherapeutic compositions and methods
Arias et al. The rise of the Enterococcus: beyond vancomycin resistance
McCarthy et al. Methicillin resistance and the biofilm phenotype in Staphylococcus aureus
Yu et al. Characterization of the Streptococcus pneumoniae NADH oxidase that is required for infection
Watanabe et al. Complete genome sequencing of three human clinical isolates of Staphylococcus caprae reveals virulence factors similar to those of S. epidermidis and S. capitis
Hiller et al. Puzzling over the pneumococcal pangenome
US20220025364A1 (en) Methods for stable genomic integration in recombinant microorganisms
Nygaard et al. Community-associated methicillin-resistant Staphylococcus aureus skin infections: advances toward identifying the key virulence factors
Borralho et al. Inhibition of pneumococcal growth and biofilm formation by human isolates of Streptococcus mitis and Streptococcus oralis
Lawrence et al. A gut-derived Streptococcus salivarius produces the novel nisin variant designated nisin G and inhibits Fusobacterium nucleatum in a model of the human distal colon microbiome
Tan et al. Exogenous glycogen utilization effects the transcriptome and pathogenicity of Streptococcus suis serotype 2
US8821860B2 (en) Targeted antimicrobials and related compositions, methods and systems
MAMMAN Identification and antibiotic susceptibility profile of methicillin and erythromycin resistant Staphylococcus aureus from clinical and environmental samples in Minna, Nigeria
Benjamin Engineering Staphylococcus epidermidis for the treatment of diabetes
Reimundo et al. dltA gene mutation in the teichoic acids alanylation system of Lactococcus garvieae results in diminished proliferation in its natural host
Mahmoud Identification of Enterococcus faecium genes involved in resistance to oxidative stress and virulence
Antezana Horizontal Transfer of Antibiotic Resistance in Streptococcus pneumoniae
Onuigbo et al. Evaluating Indigenous Lytic Bacteriophages for Activity Against Multi-Resistant Enterobacteriaceae
Reynolds The identification and characterisation of novel antimicrobial resistance genes from human and animal metagenomes
Cinthi ISOLATION AND MOLECULAR CHARACTERIZATION OF LINEZOLID-RESISTANT ENTEROCOCCI OF HUMAN, ANIMAL AND ENVIRONMENTAL ORIGIN
Mutuku Molecular Characterization And Antimicrobial Resistance Patterns Of Enterococcus Species Isolated From Patients Attending Aga Khan Hospital, Nairobi, Kenya.
Ibrahim Stress response proteins in Streptococcus pneumoniae
Rogers Class III phase variation in Staphylococcus epidermidis: Staphylococcus epidermidis icaADBC (+) and icaADBC (-) human skin colonization: The Staphylococcus epidermidis two-component regulatory system sae
Paik Molecular analysis of virulence determinants for endocarditis in Streptococcus mutans and Streptococcus sanguis

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted